림프종

425개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved425 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Genentech
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Discontinued
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 3Status Active
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

Humanized CD7 CAR-T cells (Humanized CD7 CAR-T cells)

Refractory and Relapsed T Cell Lymphoma · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 1

MB-CART19.1 Cellular Therapy (MB-CART19.1 Cellular Therapy)

Primary Central Nervous System (CNS) Lymphoma; Secondary Central Nervous System Lymphoma · Primary Central Nervous System (CNS) Lym

#PrimaryCentralNervousSystemCNSLy#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleWuhan Sian Medical Technology C…Phase 1

Second generation humanized CAR-T cells (Second generation humanized CAR-T cells)

Acute Lymphoblastic Leukemia; B Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

UCD19 CAR T Cells (UCD19 CAR T Cells)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 2

12-Day Production of Car-T Cells (12-Day Production of Car-T Cells)

Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) · Non Hodgkin Lymphoma (NHL)

#NonHodgkinLymphomaNHL#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-CD19 UCAR-NK cells (Anti-CD19 UCAR-NK cells)

B-cell Lymphoma; B-cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued

7 / 22 pages

← PreviousNext →